Paradoxical response of prostate cancer skeletal metastases to androgen deprivation therapy

Radiology Case Reports

Volumn 5, Issue 3, 2010, Pages 443-

  Wosnitzer, Brian ^a   Ghesani, Munir ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84983134037     PISSN: None     EISSN: 19300433     Source Type: Journal    
DOI: 10.2484/rcr.v5i3.443     Document Type: Article

References (7)

1. Nelson J.B. Chapter 104: Hormone therapy for prostate cancer. Campbell-Walsh urology 2007, 3082-3100. W.B. Saunders, Philadelphia. A.J. Wein (Ed.).
2. Seidenfeld J., et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000, 132(7):566-577. DOI: 200004040-00009. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10744594&query_hl=9&itool=pubmed_docsum.
3. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000, 355(9214):1491-1498. DOI: S0140673600021632. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10801170&query_hl=9&itool=pubmed_docsum.
4. Kawano H., et al. Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci U S A 2003, 100(16):9416-9421. DOI: 10.1073 / pnas.1533500100. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1287200&query_hl=9&itool=pubmed_docsum.
5. Abu E.O., et al. The localization of androgen receptors in human bone. J Clin Endocrinol Metab 1997, 82(10):3493-3497. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9329391&query_hl=9&itool=pubmed_docsum.
6. Tannock I.F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351(15):1502-1512. DOI: 351/15/1502 [pii] 10.1056 / NEJMoa040720. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15470213&query_hl=9&itool=pubmed_docsum.
7. Scher H.I., Warren M., Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 2007, 13(5):1488-1492. DOI: 13/5/1488 [pii] 10.1158 / 1078-0432.CCR-06-1885. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17332293&query_hl=9&itool=pubmed_docsum.